Sex Differences in Nonalcoholic Fatty Liver Disease: State of the Art and Identification of Research Gaps

Amedeo Lonardo, Fabio Nascimbeni, Stefano Ballestri, De Lisa Fairweather, Sanda Win, Tin A. Than, Manal F. Abdelmalek, Ayako Suzuki

Research output: Contribution to journalReview article

6 Citations (Scopus)

Abstract

Despite tremendous research advancements in nonalcoholic fatty liver disease (NAFLD), our understanding of sex differences in NAFLD remains insufficient. This review summarizes the current knowledge on sex differences in NAFLD, identifies gaps, and discusses important considerations for future research. The prevalence and severity of NAFLD are higher in men than in women during the reproductive age. However, after menopause, NAFLD occurs at a higher rate in women, suggesting that estrogen is protective. Sex differences also exist for the major risk factors of NAFLD. In general, animal models of NAFLD recapitulate the sex differences observed in patients, with more severe steatosis and steatohepatitis, more proinflammatory/profibrotic cytokines, and a higher incidence of hepatic tumors in male than female subjects. Based on computer modeling, female and male livers are metabolically distinct with unique regulators modulating sex-specific metabolic outcomes. Analysis of the literature reveals that most published clinical and epidemiological studies fail to examine sex differences appropriately. Considering the paucity of data on sex differences and the knowledge that regulators of pathways relevant to current therapeutic targets for NAFLD differ by sex, clinical trials should be designed to test drug efficacy and safety according to sex, age, reproductive stage (i.e., menopause), and synthetic hormone use. Conclusion: Sex differences do exist in the prevalence, risk factors, fibrosis, and clinical outcomes of NAFLD, suggesting that, while not yet incorporated, sex will probably be considered in future practice guidelines; adequate consideration of sex differences, sex hormones/menopausal status, age, and other reproductive information in clinical investigation and gene association studies of NAFLD are needed to fill current gaps and implement precision medicine for patients with NAFLD.

Original languageEnglish (US)
Pages (from-to)1457-1469
Number of pages13
JournalHepatology
Volume70
Issue number4
DOIs
StatePublished - Oct 1 2019

Fingerprint

Sex Characteristics
Research
Menopause
Non-alcoholic Fatty Liver Disease
Precision Medicine
Liver
Gonadal Steroid Hormones
Fatty Liver
Practice Guidelines
Epidemiologic Studies
Estrogens
Fibrosis
Animal Models
Clinical Trials
Hormones
Cytokines
Safety
Incidence

ASJC Scopus subject areas

  • Hepatology

Cite this

Sex Differences in Nonalcoholic Fatty Liver Disease : State of the Art and Identification of Research Gaps. / Lonardo, Amedeo; Nascimbeni, Fabio; Ballestri, Stefano; Fairweather, De Lisa; Win, Sanda; Than, Tin A.; Abdelmalek, Manal F.; Suzuki, Ayako.

In: Hepatology, Vol. 70, No. 4, 01.10.2019, p. 1457-1469.

Research output: Contribution to journalReview article

Lonardo, A, Nascimbeni, F, Ballestri, S, Fairweather, DL, Win, S, Than, TA, Abdelmalek, MF & Suzuki, A 2019, 'Sex Differences in Nonalcoholic Fatty Liver Disease: State of the Art and Identification of Research Gaps', Hepatology, vol. 70, no. 4, pp. 1457-1469. https://doi.org/10.1002/hep.30626
Lonardo, Amedeo ; Nascimbeni, Fabio ; Ballestri, Stefano ; Fairweather, De Lisa ; Win, Sanda ; Than, Tin A. ; Abdelmalek, Manal F. ; Suzuki, Ayako. / Sex Differences in Nonalcoholic Fatty Liver Disease : State of the Art and Identification of Research Gaps. In: Hepatology. 2019 ; Vol. 70, No. 4. pp. 1457-1469.
@article{4b13870a839a4592bc42f25e7f8ad7c7,
title = "Sex Differences in Nonalcoholic Fatty Liver Disease: State of the Art and Identification of Research Gaps",
abstract = "Despite tremendous research advancements in nonalcoholic fatty liver disease (NAFLD), our understanding of sex differences in NAFLD remains insufficient. This review summarizes the current knowledge on sex differences in NAFLD, identifies gaps, and discusses important considerations for future research. The prevalence and severity of NAFLD are higher in men than in women during the reproductive age. However, after menopause, NAFLD occurs at a higher rate in women, suggesting that estrogen is protective. Sex differences also exist for the major risk factors of NAFLD. In general, animal models of NAFLD recapitulate the sex differences observed in patients, with more severe steatosis and steatohepatitis, more proinflammatory/profibrotic cytokines, and a higher incidence of hepatic tumors in male than female subjects. Based on computer modeling, female and male livers are metabolically distinct with unique regulators modulating sex-specific metabolic outcomes. Analysis of the literature reveals that most published clinical and epidemiological studies fail to examine sex differences appropriately. Considering the paucity of data on sex differences and the knowledge that regulators of pathways relevant to current therapeutic targets for NAFLD differ by sex, clinical trials should be designed to test drug efficacy and safety according to sex, age, reproductive stage (i.e., menopause), and synthetic hormone use. Conclusion: Sex differences do exist in the prevalence, risk factors, fibrosis, and clinical outcomes of NAFLD, suggesting that, while not yet incorporated, sex will probably be considered in future practice guidelines; adequate consideration of sex differences, sex hormones/menopausal status, age, and other reproductive information in clinical investigation and gene association studies of NAFLD are needed to fill current gaps and implement precision medicine for patients with NAFLD.",
author = "Amedeo Lonardo and Fabio Nascimbeni and Stefano Ballestri and Fairweather, {De Lisa} and Sanda Win and Than, {Tin A.} and Abdelmalek, {Manal F.} and Ayako Suzuki",
year = "2019",
month = "10",
day = "1",
doi = "10.1002/hep.30626",
language = "English (US)",
volume = "70",
pages = "1457--1469",
journal = "Hepatology",
issn = "0270-9139",
publisher = "John Wiley and Sons Ltd",
number = "4",

}

TY - JOUR

T1 - Sex Differences in Nonalcoholic Fatty Liver Disease

T2 - State of the Art and Identification of Research Gaps

AU - Lonardo, Amedeo

AU - Nascimbeni, Fabio

AU - Ballestri, Stefano

AU - Fairweather, De Lisa

AU - Win, Sanda

AU - Than, Tin A.

AU - Abdelmalek, Manal F.

AU - Suzuki, Ayako

PY - 2019/10/1

Y1 - 2019/10/1

N2 - Despite tremendous research advancements in nonalcoholic fatty liver disease (NAFLD), our understanding of sex differences in NAFLD remains insufficient. This review summarizes the current knowledge on sex differences in NAFLD, identifies gaps, and discusses important considerations for future research. The prevalence and severity of NAFLD are higher in men than in women during the reproductive age. However, after menopause, NAFLD occurs at a higher rate in women, suggesting that estrogen is protective. Sex differences also exist for the major risk factors of NAFLD. In general, animal models of NAFLD recapitulate the sex differences observed in patients, with more severe steatosis and steatohepatitis, more proinflammatory/profibrotic cytokines, and a higher incidence of hepatic tumors in male than female subjects. Based on computer modeling, female and male livers are metabolically distinct with unique regulators modulating sex-specific metabolic outcomes. Analysis of the literature reveals that most published clinical and epidemiological studies fail to examine sex differences appropriately. Considering the paucity of data on sex differences and the knowledge that regulators of pathways relevant to current therapeutic targets for NAFLD differ by sex, clinical trials should be designed to test drug efficacy and safety according to sex, age, reproductive stage (i.e., menopause), and synthetic hormone use. Conclusion: Sex differences do exist in the prevalence, risk factors, fibrosis, and clinical outcomes of NAFLD, suggesting that, while not yet incorporated, sex will probably be considered in future practice guidelines; adequate consideration of sex differences, sex hormones/menopausal status, age, and other reproductive information in clinical investigation and gene association studies of NAFLD are needed to fill current gaps and implement precision medicine for patients with NAFLD.

AB - Despite tremendous research advancements in nonalcoholic fatty liver disease (NAFLD), our understanding of sex differences in NAFLD remains insufficient. This review summarizes the current knowledge on sex differences in NAFLD, identifies gaps, and discusses important considerations for future research. The prevalence and severity of NAFLD are higher in men than in women during the reproductive age. However, after menopause, NAFLD occurs at a higher rate in women, suggesting that estrogen is protective. Sex differences also exist for the major risk factors of NAFLD. In general, animal models of NAFLD recapitulate the sex differences observed in patients, with more severe steatosis and steatohepatitis, more proinflammatory/profibrotic cytokines, and a higher incidence of hepatic tumors in male than female subjects. Based on computer modeling, female and male livers are metabolically distinct with unique regulators modulating sex-specific metabolic outcomes. Analysis of the literature reveals that most published clinical and epidemiological studies fail to examine sex differences appropriately. Considering the paucity of data on sex differences and the knowledge that regulators of pathways relevant to current therapeutic targets for NAFLD differ by sex, clinical trials should be designed to test drug efficacy and safety according to sex, age, reproductive stage (i.e., menopause), and synthetic hormone use. Conclusion: Sex differences do exist in the prevalence, risk factors, fibrosis, and clinical outcomes of NAFLD, suggesting that, while not yet incorporated, sex will probably be considered in future practice guidelines; adequate consideration of sex differences, sex hormones/menopausal status, age, and other reproductive information in clinical investigation and gene association studies of NAFLD are needed to fill current gaps and implement precision medicine for patients with NAFLD.

UR - http://www.scopus.com/inward/record.url?scp=85072992302&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85072992302&partnerID=8YFLogxK

U2 - 10.1002/hep.30626

DO - 10.1002/hep.30626

M3 - Review article

C2 - 30924946

AN - SCOPUS:85072992302

VL - 70

SP - 1457

EP - 1469

JO - Hepatology

JF - Hepatology

SN - 0270-9139

IS - 4

ER -